Back to Journals » Lung Cancer: Targets and Therapy » Volume 8

Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib

Total article views   HTML views PDF downloads Totals
11,758 Dovepress* 8,386+ 1,336 9,722
PubMed Central* 3,372 482 3,854
Totals 11,758 1,818 13,576
*Since 13 October 2017
Total mentioned Facebook Delicious Reddit Twitter Others
6 1 0 0 0 5

View citations on PubMed and Google Scholar